120 related articles for article (PubMed ID: 15885576)
1. PSA elevation during prostate cryosurgery and subsequent decline.
Leibovici D; Zisman A; Lindner A; Stav K; Siegel YI
Urol Oncol; 2005; 23(1):8-11. PubMed ID: 15885576
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience.
Koppie TM; Shinohara K; Grossfeld GD; Presti JC; Carroll PR
J Urol; 1999 Aug; 162(2):427-32. PubMed ID: 10411051
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
4. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer.
Lambert EH; Bolte K; Masson P; Katz AE
Urology; 2007 Jun; 69(6):1117-20. PubMed ID: 17572198
[TBL] [Abstract][Full Text] [Related]
5. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
Alexander BM; Chen MH; Carroll P; D'Amico AV
Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
[TBL] [Abstract][Full Text] [Related]
7. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
8. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
9. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
10. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
11. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
Ganzer R; Rogenhofer S; Walter B; Lunz JC; Schostak M; Wieland WF; Blana A
Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
[TBL] [Abstract][Full Text] [Related]
12. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?
Uchida T; Illing RO; Cathcart PJ; Emberton M
BJU Int; 2006 Sep; 98(3):537-9. PubMed ID: 16925749
[TBL] [Abstract][Full Text] [Related]
13. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population.
Kobayashi T; Mitsumori K; Kawahara T; Nishizawa K; Ogura K; Ide Y
J Urol; 2006 Apr; 175(4):1281-5. PubMed ID: 16515980
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
[TBL] [Abstract][Full Text] [Related]
17. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
Zhu H; Roehl KA; Antenor JA; Catalona WJ
Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
[TBL] [Abstract][Full Text] [Related]
18. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
[TBL] [Abstract][Full Text] [Related]
19. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]